Physician profile
Daniel Bergeron
NPI 1720141864
$4,173.89
in general payments reported to CMS, 2019-2025
26 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,302 · 2020: $279 · 2021: $198 · 2022: $198 · 2023: $463 · 2024: $700 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $922.75 | 2019-2025 | |
| Abbott Laboratories | $452.09 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.15 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $286.75 | 2019-2025 | Wainua, Lokelma, Farxiga |
| Pfizer INC. | $275.19 | 2021-2025 | |
| Edwards Lifesciences Corporation | $238.93 | 2019 | |
| Merck Sharp & Dohme LLC | $211.87 | 2022-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $208.46 | 2019-2025 | Lifevest |
| Abiomed | $183.40 | 2024-2025 | Impella |
| Boston Scientific Corporation | $174.24 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $170.40 | 2022-2025 | Camzyos |
| Scpharmaceuticals INC. | $110.66 | 2025 | |
| Amgen INC. | $109.63 | 2020-2025 | Repatha, Repatha |
| Cardiovascular Systems INC. | $101.24 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $78.69 | 2019-2024 | Evkeeza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $74.04 | 2021-2025 | Onpattro |
| Bridgebio Pharma, INC. | $57.69 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $45.16 | 2025 | Assure Wcd |
| Cvrx, INC. | $32.47 | 2022 | |
| Agepha Pharma Fz LLC | $25.35 | 2025 | Lodoco |
| Medtronic, INC. | $24.08 | 2023 | Micra |
| Janssen Pharmaceuticals, INC | $23.83 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $19.14 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals, Ltd. | $18.20 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.80 | 2024 | Livalo |
| Lantheus Medical Imaging, INC. | $15.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bergeron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.